Drug intelligence / Profile preview

hepatitis B vaccine (recombinant) (GSK)

Development stage
Approved
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

Hepatitis B surface antigen vaccine is a recombinant protein subunit vaccine designed to provide active immunity against infection caused by all known subtypes of the hepatitis B virus (HBV). The vaccine consists of the viral envelope protein, hepatitis B surface antigen (HBsAg), which is produced using recombinant DNA technology, typically expressed in *Saccharomyces cerevisiae* (baker's yeast). Upon intramuscular administration, the HBsAg particles stimulate the host's immune system to produce neutralizing anti-HBs antibodies. These antibodies provide protection by binding to the virus and preventing its entry into hepatocytes. Most formulations are adsorbed onto an aluminum-based adjuvant to enhance the immunogenic response, though newer versions may utilize alternative adjuvants like TLR9 agonists. It is indicated for individuals of all ages, including neonates, to prevent HBV-related liver diseases such as chronic hepatitis, cirrhosis, and hepatocellular carcinoma.

Brand names
Engerix-BHeplisav-BRecombivax HBElovac BGeneVac-BShanvac-B
Other names
hepatitis B surface antigen vaccineHBsAg vaccinerecombinant hepatitis B vaccineHepB
02

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on hepatitis B vaccine (recombinant) (GSK).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hepatitis B vaccine (recombinant) (GSK).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call